New drug combo fails to advance in resistant breast cancer trial
NCT ID NCT01589861
First seen Apr 25, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tested a combination of two oral drugs, BKM120 and lapatinib, in people with a specific type of advanced breast cancer (HER2-positive) that had stopped responding to the standard drug trastuzumab. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Paoli-Calmettes
Marseille, 13008, France
Conditions
Explore the condition pages connected to this study.